WO2005097137A3 - Advanced quinazoline based protein kinase inhibitors - Google Patents

Advanced quinazoline based protein kinase inhibitors Download PDF

Info

Publication number
WO2005097137A3
WO2005097137A3 PCT/US2005/010974 US2005010974W WO2005097137A3 WO 2005097137 A3 WO2005097137 A3 WO 2005097137A3 US 2005010974 W US2005010974 W US 2005010974W WO 2005097137 A3 WO2005097137 A3 WO 2005097137A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
advanced
kinase inhibitors
based protein
quinazoline based
Prior art date
Application number
PCT/US2005/010974
Other languages
French (fr)
Other versions
WO2005097137A2 (en
Inventor
Congxin Liang
Original Assignee
Scripps Research Inst
Congxin Liang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Congxin Liang filed Critical Scripps Research Inst
Publication of WO2005097137A2 publication Critical patent/WO2005097137A2/en
Publication of WO2005097137A3 publication Critical patent/WO2005097137A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Hydroxy containing quinazoline based derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
PCT/US2005/010974 2004-03-31 2005-03-31 Advanced quinazoline based protein kinase inhibitors WO2005097137A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55802504P 2004-03-31 2004-03-31
US60/558,025 2004-03-31

Publications (2)

Publication Number Publication Date
WO2005097137A2 WO2005097137A2 (en) 2005-10-20
WO2005097137A3 true WO2005097137A3 (en) 2006-02-16

Family

ID=35125608

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/010968 WO2005097134A2 (en) 2004-03-31 2005-03-31 Quinazoline based protein kinase inhibitors
PCT/US2005/010974 WO2005097137A2 (en) 2004-03-31 2005-03-31 Advanced quinazoline based protein kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010968 WO2005097134A2 (en) 2004-03-31 2005-03-31 Quinazoline based protein kinase inhibitors

Country Status (1)

Country Link
WO (2) WO2005097134A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
WO2007034143A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab Quinazoline derivatives as anticancer agents
JP2009517450A (en) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
AU2012216752B2 (en) * 2006-09-11 2014-12-04 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
CL2007003158A1 (en) 2006-11-02 2008-05-16 Astrazeneca Ab PROCEDURE FOR PREPARATION OF COMPOUNDS DERIVED FROM QUINAZOLINA OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; INTERMEDIARY COMPOUNDS; PREPARATION PROCEDURE
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
ES2526718T3 (en) 2007-09-10 2015-01-14 Curis, Inc. EGFR inhibitors based on tartrate salts or quinazoline complexes containing a moiety that binds zinc
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
JP2013510163A (en) * 2009-11-06 2013-03-21 チェルシー・セラピューティクス，インコーポレイテッド Enzyme inhibitory compounds
CN101857617A (en) * 2010-04-28 2010-10-13 中国海洋大学 Quinazoline sugar derivative and preparation method and application thereof
CN102452988B (en) * 2010-10-27 2016-01-27 中国科学院化学研究所 A kind of quinazoline derivant and preparation method thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MY186126A (en) 2013-03-06 2021-06-24 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (en) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
CN104761507B (en) * 2014-01-06 2019-11-12 广东东阳光药业有限公司 Amido quinazoline derivatives and its application in drug
CN105384745A (en) * 2015-07-27 2016-03-09 北京师范大学 Crown ether cyclic quinazoline compound, preparation method therefor and application thereof in preparing tumor therapy and imaging drug
KR20190051010A (en) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. Crystalline Forms of Therapeutic Compounds and Their Uses
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3778589B1 (en) * 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CN110357858B (en) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 5-substituted difluoropiperidine compounds having blood-brain barrier crossing capability
CN110590839B (en) * 2018-06-13 2022-04-05 四川海思科制药有限公司 Levatinib derivative and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US5492915A (en) * 1990-07-24 1996-02-20 Rhone-Poulenc Rorer S.A. Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity
WO1996033980A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US6169088B1 (en) * 1996-01-10 2001-01-02 Kyowa Hakko Kogyo Co., Ltd. 1,3 diazines with platelet-derived growth factor receptor inhibitory activity
US20020091130A1 (en) * 2000-11-01 2002-07-11 James Kanter Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492915A (en) * 1990-07-24 1996-02-20 Rhone-Poulenc Rorer S.A. Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
WO1996033980A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US5770599A (en) * 1995-04-27 1998-06-23 Zeneca Limited Quinazoline derivatives
US6169088B1 (en) * 1996-01-10 2001-01-02 Kyowa Hakko Kogyo Co., Ltd. 1,3 diazines with platelet-derived growth factor receptor inhibitory activity
US20020091130A1 (en) * 2000-11-01 2002-07-11 James Kanter Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
WO2005097134A3 (en) 2006-01-26
WO2005097137A2 (en) 2005-10-20
WO2005097134A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005097137A3 (en) Advanced quinazoline based protein kinase inhibitors
WO2008033748A3 (en) Quinazoline based egfr inhibitors containing a zinc binding moiety
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
WO2008033749A3 (en) Quinazoline based egfr inhibitors containing a zinc binding moiety
WO2008033746A3 (en) Tyrosine kinase inhibitors containing a zinc binding moiety
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
HK1116349A1 (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2006069080A3 (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
HK1051188A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008033745A3 (en) Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
MX2009004771A (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase.
WO2012048259A3 (en) Substituted pyridazine carboxamide compounds
WO2005082001A3 (en) Advanced isothiazole based protein kinase inhibitors
WO2007081901A3 (en) Pyrimidinone derivatives as protein kinase inhibitors
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005053614A3 (en) Advanced indolinone based protein kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase